Heron Therapeutics Inc
Chiusa
SettoreSettore sanitario
0.32 -3.03
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
0.31
Massimo
0.34
Entrata | 2.6M -5.5M |
|---|---|
Vendite | 3M 38M |
EPS | -0.03 |
Margine di Profitto | -14.573 |
Dipendenti | 128 |
EBITDA | 2.1M -5.5M |
Utili prossimi | 3 nov 2026 |
|---|
Capitalizzazione di Mercato | -36M 61M |
|---|---|
Apertura precedente | 3.35 |
Chiusura precedente | 0.32 |
Notizie sul Sentiment di mercato
By Acuity
46%
54%
148 / 340 Classifica in Healthcare
Heron Therapeutics Inc Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Notizie correlate
Confronto tra pari
Modifica del prezzo
Heron Therapeutics Inc Previsione
Sentiment
By Acuity
148 / 340 Classifica in Settore sanitario
Notizie sul Sentiment di mercato
Prove rialziste
Volatilità
Sotto la media
Volume delle notizie (RCV)
Sopra la media
Notizie finanziarie
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$
Chi Siamo Heron Therapeutics Inc
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
